Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia

被引:45
|
作者
Persson, L [1 ]
Söderquist, B
Engervall, P
Vikerfors, T
Hansson, LO
Tidefelt, U
机构
[1] Orebro Univ Hosp, Dept Infect Dis, SE-70185 Orebro, Sweden
[2] Karolinska Inst, SE-70185 Orebro, Sweden
[3] Orebro Univ Hosp, Dept Clin Microbiol, SE-70185 Orebro, Sweden
[4] Karolinska Univ Hosp Solna, Dept Med, Div Haematol, Stockholm, Sweden
[5] Karolinska Inst, Stockholm, Sweden
[6] Univ Uppsala Hosp, Dept Med Sci Clin Chem & Pharmacol, Uppsala, Sweden
[7] Orebro Univ Hosp, Dept Clin Med, Div Haematol, SE-70185 Orebro, Sweden
关键词
neutropenia; fever; inflammation mediators; SIRS; sepsis;
D O I
10.1111/j.1600-0609.2004.00387.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In this study, we evaluated the predictive values of procalcitonin (PCT), C-reactive protein (CRP), interleukin-6 (IL-6) and serum amyloid A (SAA) for determining the clinical course in febrile neutropenic patients. Daily plasma analyses during the fever course were performed in 101 episodes with fever and chemotherapy-induced neutropenia (neutrophil count < 0.5 x 10(9)/L). Procalcitonin (PCT) and IL-6 values were significantly higher in febrile episodes in patients who developed complications. Procalcitonin with a cut-off value of <= 0.4 ng/mL or IL-6 <= 50 pg/mL 3 d after fever onset indicated daily high negative predictive values (NPVs) (91-100%) for episodes with complications. No marker could predict deterioration; however, daily low plasma concentrations of PCT or IL-6 during the first 8 d of fever were found to be a good predictor of no subsequent complications in neutropenic patients and therefore to be a helpful tool for limiting anti-microbial therapy.
引用
收藏
页码:297 / 303
页数:7
相关论文
共 50 条
  • [21] Bacteremia in adult cancer patients with apparently stable febrile neutropenia: data from a cohort of 692 consecutive episodes from a single institution
    Carmona-Bayonas, Alberto
    Jimenez Fonseca, Paula
    Font, Carme
    Martinez-Garcia, Jeronimo
    Torrella, Francisco
    Urrego, Edgar
    Castano, Patricia
    Navarrete, Agustin
    Antonio-Rebollo, Maite
    Gomez Gomez, Joaquin
    Vicente, Vicente
    Ayala, Francisco
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2014, 12 (09): : 312 - 320
  • [22] Comment on "Accuracy of the Multinational Association of Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores for predicting serious complications in adult patients with febrile neutropenia: A systematic review and meta-analysis"
    Ghajari, Hadis
    Sabour, Siamak
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 155
  • [23] Assessment of selected markers of inflammation in patients with arterial hypertension and clinical manifestation of metabolic syndrome
    Bogdanski, Pawel
    Pupek-Musialik, Danuta
    Dytfeld, Joanna
    Miczke, Anna
    Bryl, Wieslaw
    Jablecka, Anna
    Kujawska-Luczak, Magdalena
    Cymerys, Maciej
    Musialik, Katarzyna
    ARTERIAL HYPERTENSION, 2005, 9 (03): : 194 - 201
  • [24] First cycle risk of severe and febrile neutropenia in cancer patients receiving systemic chemotherapy: Results from a prospective nationwide study.
    Crawford, J
    Wolff, DA
    Culakova, E
    Poniewierski, MS
    Selby, C
    Dale, DC
    Lyman, GH
    BLOOD, 2004, 104 (11) : 607A - 608A
  • [25] Comprehensive assessment of markers of systemic inflammation and activation of immunity in HIV-positive patients receiving antiretroviral therapy
    Matuzkova, A.
    Pshenichnaya, N.
    Suladze, A.
    Dosyagaeva, L.
    Tverdokhlebova, T.
    Zhuravlev, A.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 101 : 285 - 285
  • [26] The clinical course of COVID-19 in systemic sclerosis patients, report from 150 patients
    Tamartash, Zahra
    Javinani, Ali
    Gharibdoost, Farhad
    Yekta, Reza Atef
    Mohammadzadegan, Amirmohammad
    Kavosi, Hoda
    INTERNAL AND EMERGENCY MEDICINE, 2021, 16 (07) : 2001 - 2003
  • [27] The clinical course of COVID-19 in systemic sclerosis patients, report from 150 patients
    Zahra Tamartash
    Ali Javinani
    Farhad Gharibdoost
    Reza Atef Yekta
    Amirmohammad Mohammadzadegan
    Hoda Kavosi
    Internal and Emergency Medicine, 2021, 16 : 2001 - 2003
  • [28] Interrelation between systemic inflammation markers, endothelial dysfunction and coronary heart disease clinical course after community-acquired pneumonia
    Mykhailovska, N. S.
    Kulynych, T. O.
    PATHOLOGIA, 2015, (03): : 30 - 35
  • [29] Inflammation-related differentially expressed common miRNAs in systemic autoinflammatory disorders patients can regulate the clinical course
    Akbaba, T. H.
    Akkaya-Ulum, Y. Z.
    Tavukcuoglu, Z.
    Bilginer, Y.
    Ozen, S.
    Balci-Peynircioglu, B.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (05) : S109 - S117
  • [30] Impact of subgingival periodontal treatment on systemic markers of inflammation in patients with metabolic syndrome: a systematic review of randomized clinical trials
    Chavez, Marie
    Ramirez, Asshly
    Hernandez-Vasquez, Akram
    Comande, Daniel
    Azanedo, Diego
    FRONTIERS IN ORAL HEALTH, 2025, 5